--- title: "Pre-market hot trades in US stocks: Biovie up 9.01% in pre-market; Accenture down 3.29% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/292612410.md" description: "Biovie pre-market up 9.01%; Accenture pre-market down 3.29%; NextCure pre-market up 271.10%; Picard Medical pre-market up 41.19%; Shuttle Pharmaceuticals pre-market up 37.16%" datetime: "2026-07-14T11:02:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292612410.md) - [en](https://longbridge.com/en/news/292612410.md) - [zh-HK](https://longbridge.com/zh-HK/news/292612410.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Biovie up 9.01% in pre-market; Accenture down 3.29% in pre-market **Pre-market Hot Trades in US Stocks** Biovie, up 9.01% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Accenture is down 3.29% in pre-market trading. Based on recent news, 1. On July 13, Accenture completed a $5 billion multi-tranche debt issuance, with maturities ranging from 2029 to 2036, aimed at enhancing balance sheet flexibility and supporting future growth plans. The net proceeds are expected to be approximately $4.979 billion. 2. On July 13, Accenture was rated as a leader in cybersecurity resilience services for businesses in Australia and the UK, with increased investments in AI risk management, gaining recognition in strategic and technology services. 3. On July 13, Accenture launched intelligent AI solutions for mid-market enterprises and secured a €200 million seven-year NATO contract to design, implement, and operate multi-cloud protection business networks. Recent market volatility requires attention to macroeconomic dynamics. **Top Gainers in Pre-market US Stocks** NextCure is up 271.10% in pre-market trading. Based on recent key news: 1. On July 14, NextCure announced a merger with Avere Therapeutics, with the stock price rising 93% in pre-market trading. The merged company will operate under the name Avere Therapeutics and plans to develop the AVR-001 drug through $320 million in financing. This news significantly boosted the stock price. Source: GlobeNewswire 2. On July 14, Hansoh Pharmaceutical announced its participation in Avere's targeted issuance and granted it exclusive licensing. This move accelerated the development process of AVR-001, further enhancing market confidence in the merged entity. Source: Economic Information Daily 3. On July 14, NextCure's stock price has fallen about 85% year-to-date, and the merger news provides a rebound opportunity for the stock price. Source: GlobeNewswire The biotechnology industry has seen frequent merger activities recently. Picard Medical is up 41.19% in pre-market trading. Based on recent key news: 1. On July 14, Picard Medical's stock price surged 41.19% in pre-market trading, mainly due to positive market expectations for its new products. The company's recently launched innovative medical devices have attracted investor attention, significantly driving up the stock price. 2. On July 14, Telefonaktiebolaget LM Ericsson's stock price fell 9.2% after the release of its second-quarter financial report. The report showed that its earnings did not meet market expectations, leading to a decline in investor confidence and pressure on the stock price. 3. On July 14, Braiin Ltd's stock price fell 7.8% in pre-market trading after the company announced the launch of its new product ARIA. Although the product launch previously boosted the stock price by 16%, the market remains cautious about its long-term impact, leading to a price correction The US stock market has recently experienced increased volatility and requires attention. Shuttle Pharmaceuticals rose 37.16% in pre-market trading. Based on recent news, 1. On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals to 61,271 shares. HRT Financial purchased 8,997 shares in the open market at prices ranging from $3.11 to $3.38 per share. Following this announcement, demand for the stock significantly increased, driving the share price up sharply. 2. On July 13, HRT Financial reported in Form 3 that its ownership stake in Shuttle Pharmaceuticals reached 10%. As of July 9, HRT Financial directly held 60,540 shares of common stock. This increase in ownership stake was interpreted by the market as confidence in the company's prospects, further driving up the share price. The market holds an optimistic view of the company's future, with noticeable capital inflow ### Related Stocks - [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md) - [ACN.US](https://longbridge.com/en/quote/ACN.US.md) - [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md) - [PMI.US](https://longbridge.com/en/quote/PMI.US.md) - [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md) ## Related News & Research - [Accenture Completes Acquisition of Faculty | ACN Stock News](https://longbridge.com/en/news/279223013.md) - [Accenture PLC Has Huge Unusual Put and Call Options Activity After Lower Guidance](https://longbridge.com/en/news/290465659.md) - [Two big reasons Accenture's stock is sliding in the wake of earnings](https://longbridge.com/en/news/290205441.md) - [What's next for Accenture after mixed Q3 results?](https://longbridge.com/en/news/291062457.md) - [Accenture To Acquire 100% Of RunZero And NetRise, Majority Stake In Dragos](https://longbridge.com/en/news/290188843.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**